Cullen Frost Bankers Inc. trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 27.3% during the third quarter, Holdings Channel reports. The firm owned 280 shares of the medical research company’s stock after selling 105 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Thermo Fisher Scientific were worth $82,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Hillsdale Investment Management Inc. raised its holdings in shares of Thermo Fisher Scientific by 1,208.8% in the 2nd quarter. Hillsdale Investment Management Inc. now owns 2,225 shares of the medical research company’s stock valued at $654,000 after purchasing an additional 2,055 shares during the period. Clarius Group LLC grew its stake in Thermo Fisher Scientific by 13.6% in the 3rd quarter. Clarius Group LLC now owns 2,962 shares of the medical research company’s stock valued at $863,000 after buying an additional 355 shares during the last quarter. Cohen Lawrence B grew its stake in Thermo Fisher Scientific by 2.0% in the 2nd quarter. Cohen Lawrence B now owns 10,185 shares of the medical research company’s stock valued at $2,991,000 after buying an additional 195 shares during the last quarter. Private Trust Co. NA grew its stake in Thermo Fisher Scientific by 66.7% in the 2nd quarter. Private Trust Co. NA now owns 3,273 shares of the medical research company’s stock valued at $961,000 after buying an additional 1,310 shares during the last quarter. Finally, Amica Retiree Medical Trust grew its stake in Thermo Fisher Scientific by 8.4% in the 2nd quarter. Amica Retiree Medical Trust now owns 3,184 shares of the medical research company’s stock valued at $935,000 after buying an additional 247 shares during the last quarter. 88.24% of the stock is currently owned by institutional investors.

In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 1,833 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $272.93, for a total transaction of $500,280.69. Following the transaction, the director now owns 28,592 shares in the company, valued at approximately $7,803,614.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 47,729 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $295.88, for a total transaction of $14,122,056.52. Following the transaction, the chief executive officer now owns 328,960 shares in the company, valued at approximately $97,332,684.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 51,833 shares of company stock worth $15,299,095. Company insiders own 0.45% of the company’s stock.

A number of research analysts recently commented on the stock. Barclays set a $330.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Monday, July 15th. Credit Suisse Group reiterated a “buy” rating and issued a $310.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $305.00 to $319.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. JPMorgan Chase & Co. upped their price target on shares of Thermo Fisher Scientific from $315.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Finally, ValuEngine lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $314.45.

Shares of NYSE:TMO opened at $294.65 on Friday. The company’s 50 day moving average price is $290.14 and its two-hundred day moving average price is $283.57. Thermo Fisher Scientific Inc. has a 12-month low of $208.34 and a 12-month high of $306.00. The firm has a market cap of $117.34 billion, a PE ratio of 26.50, a PEG ratio of 1.90 and a beta of 1.14. The company has a quick ratio of 1.23, a current ratio of 1.80 and a debt-to-equity ratio of 0.56.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.88 by $0.06. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. The firm had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.19 billion. During the same quarter in the prior year, the business posted $2.62 EPS. The business’s revenue was up 5.9% compared to the same quarter last year. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Tuesday, December 17th will be given a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific’s payout ratio is presently 6.83%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: What is the return on assets (ROA) ratio?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.